Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Risk factors

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

For amyloid positive individuals Aβ42/Aβ40, glial fibrillary acidic protein and p-tau181 were the top predictors of cognitive decline while Aβ42/Aβ40 was prominent for amyloid negative participants across all age groups. Socio-demographics explained a large portion of the variance in the amyloid negative individuals while the plasma biomarkers predominantly explained the variance in amyloid positive individuals (21% to 37% from the younger to the older age group). Plasma biomarkers performed similarly to MRI and cardiovascular measures when predicting cognitive outcomes and combining them with either measure resulted in better performance. Top predictors were heterogeneous between cross-sectional and longitudinal cognition models, across age groups, and amyloid status. Multimodal approaches will enhance the usefulness of plasma biomarkers through careful considerations of a study population’s socio-demographics, brain and cardiovascular health.

What this study adds

Evidence grade: Moderate

This is a cross-sectional study of 1,185 participants. This study tested whether combining Alzheimer's plasma biomarkers with MRI, cardiovascular, genetic, and lifestyle measures improves prediction of cognition. It concerns prediction, not treating, curing, or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Gebre, R. K., Graff‐Radford, J., Ramanan, V. K., Raghavan, S., Hofrenning, E. I., Przybelski, S. A., et al. (2024). Can integration of Alzheimer’s plasma biomarkers with MRI, cardiovascular, genetics, and lifestyle measures improve cognition prediction? Brain Communications. https://doi.org/10.1093/braincomms/fcae300

Vancouver

Gebre RK, Graff‐Radford J, Ramanan VK, Raghavan S, Hofrenning EI, Przybelski SA, et al. Can integration of Alzheimer’s plasma biomarkers with MRI, cardiovascular, genetics, and lifestyle measures improve cognition prediction? Brain Communications. 2024. doi:10.1093/braincomms/fcae300. PMID: 39291164.

BibTeX

@article{gebre2024-39291164,
  author  = {Gebre, Robel K and Graff‐Radford, Jonathan and Ramanan, Vijay K. and Raghavan, Sheelakumari and Hofrenning, Ekaterina I. and Przybelski, Scott A. and Nguyen, Aivi T. and Lesnick, Timothy G. and others},
  title   = {{Can integration of Alzheimer’s plasma biomarkers with MRI, cardiovascular, genetics, and lifestyle measures improve cognition prediction?}},
  journal = {Brain Communications},
  year    = {2024},
  doi     = {10.1093/braincomms/fcae300},
  pmid    = {39291164},
  url     = {https://doi.org/10.1093/braincomms/fcae300}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study tested whether combining Alzheimer's plasma biomarkers with MRI, cardiovascular, genetic, and lifestyle measures improves prediction of cognition. It concerns prediction, not treating, curing, or preventing Alzheimer's disease.

Study details

How this study scored 53/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 0 of 4; Study design 4 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 53 of 100.53 of 100 points earned47 not earned

Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Brain Communications)
Journal's citation record 0 / 4 Brain Communications: journal h-index 67 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 3 / 4 1,185 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 6 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.5 citations a year over 4 year(s) since 2024
Impact for its field and year 2 / 6 Cited 1.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Prashanthi Vemuri: h-index 106 (OpenAlex, whole career)
Institution's track record 2 / 3 Mayo Clinic: institution h-index 1,606 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39291164)
Free to read 2 / 2 Free to read
Total 53 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Risk factors from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk factors

See all studies in Risk factors →